Irrisept O.R. wound irrigation and treatment system
According to the Mayo Clinic, "Methicillin-resistant Staphylococcus Aureus (MRSA) infection is caused by a strain of staph bacteria that's become resistant to the antibiotics commonly used to treat ordinary staph infections." And, "Most MRSA infections occur in people who've been in hospitals or other health care settings". MRSA is a very real concern for hospitals and patients, and is a source of costly and dangerous infections.
Slingshot designers and engineers worked with Irrimax to develop a device which helps reduce the possibility of MRSA infection by introducing a solution of Chlorhexadine (a powerful, and long lasting antiseptic) onto wounds and surgical sites. Further, the device developed by Slingshot reduces health care costs by speeding up the wound irrigation procedure and eliminating the chance of accidental needle sticks.
Slingshot’s extensive involvement in the program included early concept work, developing the product for high-volume manufacture, and launching Irrimax Corporation. Slingshot also assisted with the development of corporate ID assets, developing the website, managing plastic part suppliers, managing the set up of a manufacturing facility and associated production equipment, and managing FDA compliance issues and associated documentation.
Slingshot’s key design challenge was to create a bottle that was ergonomically appropriate and thin enough to be squeezed easily, yet was robust enough to survive steam sterilization.
The Slingshot team delivered a quality product on time and within budget. The product launched in just 18 months and is being distributed nationwide by Cardinal Health.